Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab

Date

21 Oct 2023

Session

Poster session 04

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Georg Evers

Citation

Annals of Oncology (2023) 34 (suppl_2): S746-S754. 10.1016/S0923-7534(23)01266-8

Authors

G. Evers1, L.E. Reitnauer1, D.C.C. Christoph2, W.M. Brueckl3, M. Wiesweg4, F. Glanemann4, M. Webendoerfer4, C. Kropf5, F. Acker6, A. Hund7, W. Schütte8, P. Hoffknecht9, A. Kerkhoff1, M. Mohr1, G. Lenz1, N. Frost10, T.R. Overbeck7, M. Sebastian6, A. Bleckmann1

Author affiliations

  • 1 Department Of Medicine A, UKM - University Hospital Muenster, 48149 - Muenster/DE
  • 2 Medical Oncology / Hematology Department, KEM | Evang. Kliniken Essen-Mitte gGmbH, 45136 - Essen/DE
  • 3 Dept. Of Internal Medicine 3, Klinikum Nuernberg Nord, 90419 - Nürnberg/DE
  • 4 Department Of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 5 Pulmonology Dept., University Hospital Ulm, 89081 - Ulm/DE
  • 6 Department Of Hematology And Oncology, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), 60590 - Frankfurt am Main/DE
  • 7 Department Of Hematology And Clinical Oncology, Universitätsmedizin Göttingen, 37075 - Goettingen/DE
  • 8 Department Of Internal Medicine Ii, Hospital Martha-Maria Halle-Doelau, 06120 - Halle/DE
  • 9 Department Of Thoracic Oncology, Franziskus-Hospital Harderberg - Niels-Stensen-Kliniken GmbH, 49124 - Georgsmarienhütte/DE
  • 10 Department Of Infectious Diseases And Pneumonology, Universitätsklinik Charité - Campus Virchow Klinikum, 13353 - Berlin/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1300P

Background

Despite recent advances in treatment of locally advanced non-small cell lung cancer (NSCLC) most patients suffer from relapse following treatment with chemoradiotherapy and consolidative Durvalumab. To date, no treatment standards have yet been established in current guidelines. As well, there is a paucity of data regarding effectiveness of different treatment options in relapsed/refractory (r/r) NSCLC. Here, we present preliminary data on treatment and outcome of r/r NSCLC patients in a real word setting.

Methods

So far, in this analysis we assessed patients from 10 German lung cancer centers undergoing treatment for r/r NSCLC between 06/2017 and 05/2023. Primarily, overall survival (OS) and progression-free survival (PFS) was estimated in this cohort and compared to historical outcomes. In addition, both different treatment options and OS/PFS were compared between subgroups. Last follow up will be assessed by June 30, 2023.

Results

N = 122 patients were retrospectively evaluated. Median OS from initial lung cancer diagnosis was 25.8 months (20.6 – 30.9) for the entire patient cohort. Following diagnosis of r/r disease median OS and PFS was 11.7 months (9.2 – 14.2) and 6.4 months (5.2 – 7.6), respectively. In relation to all patients undergoing systemic therapy as first -line treatment (70.5%), choice of systemic agents varied, with checkpoint inhibitors (with or without chemotherapy, 34.9%) most commonly administered, followed by platinum- (30.2%) or single agent-based chemotherapy (27.9%) and targeted therapies (7.0%). Interestingly, patients treated with targeted therapy or checkpoint inhibitor-based therapy benefited in terms of overall survival compared with patients who received chemotherapy alone.

Conclusions

Patients suffering from r/r disease represent a distinct patient population showing a dismal prognosis. However, choice of first-line therapy might affect overall survival. Besides improving early detection of NSCLC recurrence prospective clinical trials are warranted to further guide treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

D.C.C. Christoph: Financial Interests, Other: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Merck Sharp Dohme, Novartis, Novocure, Pfizer, Roche, Sanofi, Takeda. M. Wiesweg: Financial Interests, Personal, Invited Speaker: Amgen, Roche, Takeda, GSK, AstraZeneca; Financial Interests, Personal, Advisory Board: GSK, Novartis, Pfizer, Roche, Janssen, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Takeda; Financial Interests, Institutional, Funding: Bristol Myers Squibb. T.R. Overbeck: Financial Interests, Personal, Other: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.